| Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] |
| | | | | | | Fair Value Measurements at | |
| | | | | | | March 31, 2025 | |
| | | | | | | Quoted | | | Significant | | | | | |
| | | | | | | Prices | | | Other | | | Significant | |
| | | | | | | in Active | | | Observable | | | Unobservable | |
| | | | | | | Markets | | | Inputs | | | Inputs | |
| | | Total | | | (Level 1) | | | (Level 2) | | | (Level 3) | |
| Assets: | | | | | | | | | | | | | | | | |
| Haywood derivative | | $ | 14,942 | | | $ | — | | | $ | 14,942 | | | $ | — | |
| AST derivative | | | 392,000 | | | | — | | | | 392,000 | | | | — | |
| Total assets measured at fair value | | $ | 406,942 | | | $ | — | | | $ | 406,942 | | | $ | — | |
| | | | | | | | | | | | | | | | | |
| Liabilities: | | | | | | | | | | | | | | | | |
| 2025 Kips Bay convertible debt derivative | | $ | 920,000 | | | $ | — | | | $ | — | | | $ | 920,000 | |
| LINICO acquisition-related payable derivative | | | 309,000 | | | | — | | | | 309,000 | | | | — | |
| Marathon SAFE Note | | | 12,000,000 | | | | — | | | | — | | | | 12,000,000 | |
| Total liabilities measured at fair value | | $ | 13,229,000 | | | $ | — | | | $ | 309,000 | | | $ | 12,920,000 | |
| | | | | | | Fair Value Measurements at | |
| | | | | | | December 31, 2024 | |
| | | | | | | Quoted | | | Significant | | | | | |
| | | | | | | Prices | | | Other | | | Significant | |
| | | | | | | in Active | | | Observable | | | Unobservable | |
| | | | | | | Markets | | | Inputs | | | Inputs | |
| | | Total | | | (Level 1) | | | (Level 2) | | | (Level 3) | |
| Assets: | | | | | | | | | | | | | | | | |
| Haywood derivative | | $ | 1,529,850 | | | $ | — | | | $ | 1,529,850 | | | $ | — | |
| Total assets measured at fair value | | $ | 1,529,850 | | | $ | — | | | $ | 1,529,850 | | | $ | — | |
| | | | | | | | | | | | | | | | | |
|
| Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] |
| | | For the Three-Months Ended March 31, 2025 | |
| | | As of December 31, 2024 | | | (Additions) Deductions | | | Change in Fair Value | | | Payments for Decrease in Contractual Stock Consideration | | | As of March 31, 2025 | |
| 2025 Kips Bay convertible debt derivative | | $ | — | | | $ | (1,421,645 | ) | | $ | 501,645 | | | $ | — | | | $ | (920,000 | ) |
| LINICO acquisition-related payable derivative | | | — | | | | (340,000 | ) | | | 31,000 | | | | — | | | | (309,000 | ) |
| AST derivative | | | — | | | | 480,540 | | | | (88,540 | ) | | | — | | | | 392,000 | |
| Haywood derivative | | | 1,529,850 | | | | — | | | | (1,634,908 | ) | | | 120,000 | | | | 14,942 | |
| Total derivative assets (liabilities) at fair value | | $ | 1,529,850 | | | $ | (1,281,105 | ) | | $ | (1,190,803 | ) | | $ | 120,000 | | | $ | (822,058 | ) |
| | | For the Three-Months Ended March 31, 2024 | |
| | | As of December 31, 2023 | | | (Additions) Deductions | | | Change in Fair Value | | | Payments for Decrease in Contractual Stock Consideration | | | As of March 31, 2024 | |
| 2023 Kips Bay convertible debt derivative | | $ | (1,360,000 | ) | | $ | (596,601 | ) | | $ | 516,601 | | | $ | — | | | $ | (1,440,000 | ) |
| LINICO acquisition-related payable derivative | | | (2,383,162 | ) | | | — | | | | (510,163 | ) | | | — | | | | (2,893,325 | ) |
| Haywood derivative | | | (875,000 | ) | | | — | | | | (285,000 | ) | | | — | | | | (1,160,000 | ) |
| GenMat derivative | | | (781,966 | ) | | | — | | | | (477,556 | ) | | | 1,500,000 | | | | 240,478 | |
| Total derivative liabilities at fair value | | $ | (5,400,128 | ) | | $ | (596,601 | ) | | $ | (756,118 | ) | | $ | 1,500,000 | | | $ | (5,252,847 | ) |
|